Future Treatment of Patients With Alopecia Areata

February 26, 2025

Ryan Haumschild, PharmD, MS, MBA
Amy McMichael, MD

Opinion

Video

Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

Now Viewing

EP: 20.Future Treatment of Patients With Alopecia Areata

EP: 21.Final Takeaways From the Panelists

Video content above is prompted by the following:

McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies?
1. How do you think payers should anticipate covering AA in the next few years?
Friedland: What do you see as the biggest unmet needs for patients with AA and how can these be improved in the future?